Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupTSXV:GSD 39 FCF Yield % is -41.73 as of Aug. 02, 2026. GuruFocus rates TSXV:GSD with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Devonian Health Group ranks worse than 80.21% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Devonian Health Group FCF Yield % Related Terms
Devonian Health Group FCF Yield % Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:GSD vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, Devonian Health Group's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (TSXV:GSD) has a FCF Yield % of -41.73 as of Aug. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #1131 out of 1410 companies in the Biotechnology industry, placing it in the top 80.2%.
Is Devonian Health Group's FCF Yield % too high?
Devonian Health Group's current FCF Yield % is -41.73. Based on the distribution chart, Devonian Health Group ranks #1131 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Devonian Health Group has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #1131 out of 1410 companies for FCF Yield %. This places Devonian Health Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current FCF Yield % is -41.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Devonian Health Group (TSXV:GSD) has a current FCF Yield % of -41.73. The current FCF Yield % is -41.73. Devonian Health Group's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Devonian Health Group (TSXV:GSD), the current FCF Yield % is -41.73 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
39GF Score
Get the complete analysis for TSXV:GSD
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:GSD has been successfully added to your 
